|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/04/17 Actinium Pharmaceuticals, Inc. 10-Q 6/30/17 60:3.8M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 369K
2: EX-10.1 Assignment and Consent Agreement, Dated June 6, HTML 37K
2017, Among 275 Madison Avenue Rpw 1 LLC, 275
Madison Avenue Rpw 2, LLC, Actinium
Pharmaceuticals, Inc. and Relmada Therapeutics,
Inc.
3: EX-10.3 Amended and Restated License Agreement, Dated June HTML 33K
8, 2017, Between Actinium Pharmaceuticals, Inc.
and Relmada Therapeutics, Inc.
4: EX-10.4 Offer Letter; Dated May 26, 2017, by and Between HTML 78K
Actinium Pharmaceuticals, Inc. and Dr. Nitya G.
Ray
5: EX-10.5 Amended and Restated At-The-Market Market Issuance HTML 251K
Sales Agreement, Dated July 3, 2017, Among Fbr
Capital Markets & Co., Jonestrading Institutional
Services LLC, and Mlv & Co. LLC.
6: EX-10.6 Agreement, Dated June 6, 2017, by and Between HTML 35K
Actinium Pharmaceuticals, Inc. and Sergio Traversa
7: EX-10.7 Consulting Agreement, Dated May 22, 2017, by and HTML 65K
Between Actinium Pharmaceuticals, Inc. and Dragan
Cicic
8: EX-10.8 Separation and Settlement Agreement, Dated May 12, HTML 60K
2017, by and Between Actinium Pharmaceuticals,
Inc. and Kaushik Dave
9: EX-10.9 Separation and Settlement Agreement, Dated May 12, HTML 57K
2017, by and Between Actinium Pharmaceuticals,
Inc. and Dragan Cicic
10: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
20: R1 Document and Entity Information HTML 40K
21: R2 Consolidated Balance Sheets (Unaudited) HTML 84K
22: R3 Consolidated Balance Sheets (Unaudited) HTML 37K
(Parenthetical)
23: R4 Consolidated Statements of Operations (Unaudited) HTML 53K
24: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 83K
25: R6 Description of Business and Summary of Significant HTML 67K
Accounting Policies
26: R7 Related Party Transactions HTML 31K
27: R8 Prepaid Expenses and Other Current Assets HTML 26K
28: R9 Property and Equipment HTML 28K
29: R10 Derivatives HTML 47K
30: R11 Commitments and Contingencies HTML 56K
31: R12 Equity HTML 65K
32: R13 Subsequent Events HTML 24K
33: R14 Description of Business and Summary of Significant HTML 106K
Accounting Policies (Policies)
34: R15 Description of Business and Summary of Significant HTML 35K
Accounting Policies (Tables)
35: R16 Related Party Transactions (Tables) HTML 22K
36: R17 Prepaid Expenses and Other Current Assets (Tables) HTML 25K
37: R18 Property and Equipment (Tables) HTML 25K
38: R19 Derivatives (Tables) HTML 43K
39: R20 Commitments and Contingencies (Tables) HTML 30K
40: R21 Equity (Tables) HTML 44K
41: R22 Description of Business and Summary of Significant HTML 30K
Accounting Policies (Details)
42: R23 Description of Business and Summary of Significant HTML 27K
Accounting Policies (Details 1)
43: R24 Description of Business and Summary of Significant HTML 31K
Accounting Policies (Details Textual)
44: R25 Related Party Transactions (Details) HTML 25K
45: R26 Related Party Transactions (Details Textual) HTML 32K
46: R27 Prepaid Expenses and Other Current Assets HTML 30K
(Details)
47: R28 Property and Equipment (Details) HTML 34K
48: R29 Property and Equipment (Details Textual) HTML 22K
49: R30 Derivatives (Details) HTML 31K
50: R31 Derivatives (Details 1) HTML 49K
51: R32 Derivatives (Details Textual) HTML 30K
52: R33 Commitments and Contingencies (Details) HTML 39K
53: R34 Commitments and Contingencies (Details 1) HTML 35K
54: R35 Commitments and Contingencies (Details Textual) HTML 131K
55: R36 Equity (Details) HTML 69K
56: R37 Equity (Details Textual) HTML 108K
57: R38 Subsequent Events (Details) HTML 47K
59: XML IDEA XML File -- Filing Summary XML 92K
58: EXCEL IDEA Workbook of Financial Reports XLSX 47K
17: EX-101.INS XBRL Instance -- atnm-20170630 XML 744K
19: EX-101.CAL XBRL Calculations -- atnm-20170630_cal XML 87K
14: EX-101.DEF XBRL Definitions -- atnm-20170630_def XML 356K
15: EX-101.LAB XBRL Labels -- atnm-20170630_lab XML 883K
16: EX-101.PRE XBRL Presentations -- atnm-20170630_pre XML 566K
18: EX-101.SCH XBRL Schema -- atnm-20170630 XSD 126K
60: ZIP XBRL Zipped Folder -- 0001213900-17-008244-xbrl Zip 93K
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Sandesh Seth, certify that:
| 1. | I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report; |
| 4. | I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals; | |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d) | Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b) | Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: August 4, 2017 | By: | /s/ Sandesh Seth |
| Sandesh Seth | ||
|
Chairman & CEO (Duly Authorized Officer and Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/4/17 | 4, SC 13G | ||
| For Period end: | 6/30/17 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/22 Actinium Pharmaceuticals, Inc. 10-K 12/31/21 56:4.2M EdgarAgents LLC/FA 3/31/21 Actinium Pharmaceuticals, Inc. 10-K 12/31/20 56:3.5M EdgarAgents LLC/FA |